• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本活体供肝肝移植治疗肝细胞癌标准的全国性队列研究。

Japanese living donor liver transplantation criteria for hepatocellular carcinoma: nationwide cohort study.

机构信息

Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Medical Centre for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.

出版信息

BJS Open. 2024 Jul 2;8(4). doi: 10.1093/bjsopen/zrae079.

DOI:10.1093/bjsopen/zrae079
PMID:39092977
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11295212/
Abstract

BACKGROUND

Validating the expanded criteria for living donor liver transplantation for hepatocellular carcinoma using national data is highly significant. The aim of this study was to evaluate the validity of the new Japanese criteria for living donor liver transplantation for hepatocellular carcinoma patients and identify factors associated with a poor prognosis using the Japanese national data set.

METHODS

The study population comprised patients who underwent living donor liver transplantation for hepatocellular carcinoma at 37 centres in Japan between 2010 and 2018. In a nationwide survey, the overall survival and recurrence-free survival rates were evaluated based on the new Japanese criteria for applying the 5-5-500 rule when extending the indication beyond the Milan criteria. Prognostic factors within the Japanese criteria were determined using the Cox proportional hazards model.

RESULTS

Patients within (485 patients) and beyond (31 patients) the Japanese criteria exhibited 5-year overall survival rates of 81% and 58% and 5-year recurrence-free survival rates of 77% and 48% respectively. Patients who met the Milan criteria, but not the 5-5-500 rule, had poorer outcomes. Multivariate analysis for 474 patients identified a neutrophil-to-lymphocyte ratio greater than or equal to 5 and a history of hepatectomy as independent risk factors.

CONCLUSION

This nationwide survey confirms the validity of the Japanese criteria. The poor prognostic factors within the Japanese criteria include a neutrophil-to-lymphocyte ratio greater than or equal to 5 and previous hepatectomy.

摘要

背景

使用国家数据验证扩大的肝癌活体供肝移植标准具有重要意义。本研究旨在使用日本国家数据集评估新的日本肝癌活体供肝移植标准的有效性,并确定与不良预后相关的因素。

方法

研究人群包括 2010 年至 2018 年在日本 37 个中心接受活体供肝移植治疗肝癌的患者。在一项全国性调查中,根据将米兰标准的适应证扩大至 5-5-500 规则时应用新的日本标准,评估总体生存率和无复发生存率。使用 Cox 比例风险模型确定日本标准内的预后因素。

结果

符合日本标准内(485 例)和标准外(31 例)的患者 5 年总生存率分别为 81%和 58%,5 年无复发生存率分别为 77%和 48%。符合米兰标准但不符合 5-5-500 规则的患者预后较差。对 474 例患者的多变量分析确定,中性粒细胞与淋巴细胞比值大于或等于 5 和肝切除术史为独立的危险因素。

结论

本全国性调查证实了日本标准的有效性。日本标准内的不良预后因素包括中性粒细胞与淋巴细胞比值大于或等于 5 和既往肝切除术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6145/11295212/e6977287d7b7/zrae079f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6145/11295212/bd6e4353ecf3/zrae079f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6145/11295212/eb371b26e488/zrae079f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6145/11295212/e6977287d7b7/zrae079f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6145/11295212/bd6e4353ecf3/zrae079f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6145/11295212/eb371b26e488/zrae079f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6145/11295212/e6977287d7b7/zrae079f3.jpg

相似文献

1
Japanese living donor liver transplantation criteria for hepatocellular carcinoma: nationwide cohort study.日本活体供肝肝移植治疗肝细胞癌标准的全国性队列研究。
BJS Open. 2024 Jul 2;8(4). doi: 10.1093/bjsopen/zrae079.
2
Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.供体肝移植后肝细胞肝癌患者的临床结局。
World J Gastroenterol. 2013 Aug 7;19(29):4737-44. doi: 10.3748/wjg.v19.i29.4737.
3
Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.符合米兰标准的肝细胞癌患者在活体肝移植前进行局部区域治疗的有效性。
Transplant Proc. 2012 Mar;44(2):403-8. doi: 10.1016/j.transproceed.2012.01.067.
4
Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study.基于日本全国性调查的扩大活体供肝肝移植标准用于肝细胞癌患者:5-5-500 规则-一项回顾性研究。
Transpl Int. 2019 Apr;32(4):356-368. doi: 10.1111/tri.13391. Epub 2019 Jan 18.
5
Living donor liver transplantation for hepatocellular carcinoma.肝细胞癌的活体供肝肝移植
Transplant Proc. 2012 Jul-Aug;44(6):1713-6. doi: 10.1016/j.transproceed.2012.05.033.
6
Living donor liver transplantation for recurrent hepatocellular carcinoma after liver resection.肝切除术后复发肝细胞癌的活体供肝肝移植。
Surgery. 2012 Jan;151(1):55-60. doi: 10.1016/j.surg.2011.06.032. Epub 2011 Sep 22.
7
Living Donor Liver Transplantation: The Optimal Curative Treatment for Hepatocellular Carcinoma Even Beyond Milan Criteria.活体肝移植:即使超出米兰标准,也是肝细胞癌的最佳治愈性治疗手段。
Cancer Control. 2021 Jan-Dec;28:10732748211011960. doi: 10.1177/10732748211011960.
8
Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study.术前氟脱氧葡萄糖-正电子发射断层扫描在预测肝细胞癌患者肝移植后肿瘤复发中的意义:一项日本多中心研究。
J Hepatobiliary Pancreat Sci. 2017 Jan;24(1):49-57. doi: 10.1002/jhbp.412.
9
Small-for-size grafts increase recurrence of hepatocellular carcinoma in liver transplantation beyond milan criteria.小体积供肝移植增加了米兰标准以外肝癌肝移植的复发率。
Liver Transpl. 2018 Jan;24(1):35-43. doi: 10.1002/lt.24868.
10
Poor oncologic outcomes of hepatocellular carcinoma patients with intra-abdominal infection after hepatectomy.肝癌患者肝切除术后发生腹腔内感染的肿瘤学预后较差。
World J Gastroenterol. 2015 May 14;21(18):5598-606. doi: 10.3748/wjg.v21.i18.5598.

引用本文的文献

1
Prognostic value of neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma receiving curative therapies: a systematic review and meta-analysis.接受根治性治疗的肝细胞癌患者中性粒细胞与淋巴细胞比值的预后价值:一项系统评价和荟萃分析
BMC Cancer. 2025 Mar 29;25(1):571. doi: 10.1186/s12885-025-13972-w.

本文引用的文献

1
Salvage versus Primary Liver Transplantation for Hepatocellular Carcinoma: A Twenty-Year Experience Meta-Analysis.肝细胞癌挽救性肝移植与原位肝移植:一项二十年经验的荟萃分析
Cancers (Basel). 2022 Jul 16;14(14):3465. doi: 10.3390/cancers14143465.
2
Alpha-fetoprotein slope over 7.5 ng/ml over 3 months before liver transplantation for hepatocellular carcinoma predicts recurrence even after controlling for alpha-fetoprotein at liver transplantation.在肝细胞癌肝移植前3个月内甲胎蛋白斜率超过7.5 ng/ml,即使在控制肝移植时的甲胎蛋白水平后,仍可预测复发。
Liver Transpl. 2023 Feb 1;29(2):233-235. doi: 10.1002/lt.26541. Epub 2023 Jan 17.
3
Prediction of Early Recurrence After Surgery for Liver Tumor (ERASL): An International Validation of the ERASL Risk Models.
肝肿瘤手术后早期复发的预测(ERASL):ERASL 风险模型的国际验证。
Ann Surg Oncol. 2021 Dec;28(13):8211-8220. doi: 10.1245/s10434-021-10235-3. Epub 2021 Jul 7.
4
Clinical value and limitations of the preoperative C-reactive-protein-to-albumin ratio in predicting post-operative morbidity and mortality after deceased-donor liver transplantation: a retrospective single-centre study.术前C反应蛋白与白蛋白比值预测脑死亡供体肝移植术后发病率和死亡率的临床价值及局限性:一项回顾性单中心研究
Transpl Int. 2021 Aug;34(8):1468-1480. doi: 10.1111/tri.13957. Epub 2021 Jul 4.
5
Association between neutrophil-lymphocyte ratio change during living donor liver transplantation and graft survival.供体肝移植过程中中性粒细胞与淋巴细胞比值变化与移植物存活的关系。
Sci Rep. 2021 Feb 18;11(1):4199. doi: 10.1038/s41598-021-83814-9.
6
Neutrophil-to-Lymphocyte Ratio Predicts High-Risk Explant Features and Waitlist Survival But Is Not Independently Associated With Recurrence or Survival Following Liver Transplantation for Hepatocellular Carcinoma.中性粒细胞与淋巴细胞比值预测高风险移植特征和等待移植期间的生存情况,但与肝癌肝移植后复发或生存情况无独立相关性。
Liver Transpl. 2021 Jun;27(6):818-829. doi: 10.1002/lt.26010.
7
Neutrophil-to-lymphocyte ratio predicts early acute cellular rejection in living donor liver transplantation.中性粒细胞与淋巴细胞比值可预测活体肝移植早期急性细胞排斥反应。
Ann Surg Treat Res. 2020 Dec;99(6):337-343. doi: 10.4174/astr.2020.99.6.337. Epub 2020 Nov 26.
8
Salvage living donor liver transplantation for hepatocellular carcinoma recurrence after hepatectomy: Quantitative prediction using ADV score.挽救性亲体肝移植治疗肝癌切除术后复发:ADV 评分的定量预测。
J Hepatobiliary Pancreat Sci. 2021 Nov;28(11):1000-1013. doi: 10.1002/jhbp.863. Epub 2020 Dec 22.
9
Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-transplant Clinical Outcome.桥接局部区域治疗对肝细胞癌移植后临床结局的影响。
Clin Transplant. 2020 Dec;34(12):e14128. doi: 10.1111/ctr.14128. Epub 2020 Nov 20.
10
Inflammation-Based Prognostic Scores in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Transplantation.肝移植术后乙型肝炎病毒相关肝细胞癌患者基于炎症的预后评分
J Hepatocell Carcinoma. 2020 Jul 7;7:101-106. doi: 10.2147/JHC.S259992. eCollection 2020.